0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 1-20 of 34 Articles
Viewpoint 
Stuart B. Murray, PhD; Katharine L. Loeb, PhD; Daniel Le Grange, PhD

This Viewpoint argues that individualized exposure therapy distinguishing between fear of food vs weight gain is important for successful management of anorexia nervosa.

Original Investigation  FREE
Maria A. Oquendo, MD; Hanga Galfalvy, PhD; Gregory M. Sullivan, MD; Jeffrey M. Miller, MD; Matthew M. Milak, MD; M. Elizabeth Sublette, MD, PhD; Sebastian Cisneros-Trujillo, MD; Ainsley K. Burke, PhD; Ramin V. Parsey, MD, PhD; J. John Mann, MD
Includes: Supplemental Content

Importance  Biomarkers that predict suicidal behavior, especially highly lethal behavior, are urgently needed. In cross-sectional studies, individuals with depression who attempt suicide have lower midbrain serotonin transporter binding potential compared with those who do not attempt suicide, and higher serotonin1A binding potential in the raphe nuclei ...

Comment & Response 
Nadia Solowij, PhD; Valentina Lorenzetti, PhD; Murat Yücel, PhD

To the Editor With rapidly shifting legislation worldwide in relation to recreational and medicinal cannabis use, the review by Volkow et al1 is timely. We highlight several additional noteworthy issues for consideration.

Comment & Response 
Nora D. Volkow, MD

In Reply We appreciate the additional points that Solowij et al contribute to this important discussion.1 The uncertainty regarding the relationship between exposure parameters and neural substrates on one hand and persistence or decay of cognitive impairment and the associated neurobiological changes on the other is indeed ...

Original Investigation 
Jayashri Kulkarni, MBBS, PhD; Emorfia Gavrilidis, BAppSc; Stella M. Gwini, MSc; Roisin Worsley, MBBS, FRACP; Jasmin Grigg, PhD; Annabelle Warren, MBBS; Caroline Gurvich, DPsych; Heather Gilbert, RN; Michael Berk, MBBCh, PhD; Susan R. Davis, MBBS, PhD
Includes: Supplemental Content

Importance  A substantial proportion of women with schizophrenia experience debilitating treatment-refractory symptoms. The efficacy of estrogen in modulating brain function in schizophrenia has to be balanced against excess exposure of peripheral tissue. Raloxifene hydrochloride is a selective estrogen receptor modulator (mixed estrogen agonist/antagonist) with potential psychoprotective effects ...

Research Letter 
Anna Lembke, MD; Jonathan H. Chen, MD, PhD

This pharmacoepidemiology study uses Medicare Part D data to describe the use of buprenorphine-naloxone in the United States in 2013.

Comment & Response 
Feras Ali Mustafa, MD

To the Editor Clozapine was not shown to be superior to other antipsychotic drugs in the comprehensive meta-analysis conducted by Samara et al.1 This finding is in stark contrast to the landmark randomized clinical trial by Kane et al,2 which has been backed by the cumulative ...

Comment & Response 
Joseph P. McEvoy, MD

To the Editor Does clozapine offer additional therapeutic benefit to patients who have received inadequate therapeutic benefit from other antipsychotic medications (APMs)? This is the question Samara et al1 aimed to address in their article in JAMA Psychiatry.

Comment & Response 
Myrto T. Samara, MD; Stefan Leucht, MD

In Reply We disagree with the comment by Mustafa that meta-analysis as a method is the reason for the unexpected results in our article.1 Meta-analysis is just reflecting the results of the included studies. Our meta-analysis confirmed that clozapine is better than first-generation antipsychotics. The unexpected finding ...

Viewpoint  FREE
Charles G. Kels, JD; Jennifer A. Bernstein, JD, MPH; Y. Tony Yang, ScD, LLM, MPH

This Viewpoint explores the nexus between mental health records and firearms background checks and examines implications for psychiatrists.

Editorial 
Jan Volavka, MD, PhD

Most patients with psychosis are not violent. Nevertheless, such patients are more likely to engage in violent behavior than are members of the general population.1 Dynamic (time-variant) modifiable risk factors for violence in patients with psychosis include comorbid alcohol and substance use disorders, nonadherence to treatment, impaired ...

Original Investigation 
Amir Sariaslan, PhD; Paul Lichtenstein, PhD; Henrik Larsson, PhD; Seena Fazel, MD
Includes: Supplemental Content

Importance  Absolute and relative risks of violence are increased in patients with psychotic disorders, but the contribution of triggers for violent acts to these risks is uncertain.

Objective  To examine whether a range of triggers for violent acts are associated with risks of violence in patients ...

Editorial: Triggering Violence in Psychosis; Jan Volavka, MD, PhD
Comment & Response 
Daniel L. C. Costa, MD; Juliana Belo Diniz, MD, PhD; Eurípedes Constantino Miguel, MD, PhD

To the Editor In JAMA Psychiatry, Grant and colleagues1 demonstrated the efficacy of N-acetylcysteine (NAC) in the treatment of excoriation disorder (ED). The same group had previously reported the benefits of NAC for adults with trichotillomania (TTM).2 In both studies, NAC was used in ...

Comment & Response 
Eric W. Leppink, BA; Samuel R. Chamberlain, MD, PhD; Jon E. Grant, JD, MD, MPH

In Reply Costa and colleagues raise important issues regarding how grooming disorders (GDs) should be optimally treated and classified.

In the Original Investigation titled “Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clinical Trial,”1 published online May 12, 2016, there was an omission in the Methods section and errors in Figure 2. The sentence describing the Cohen d calculation in the Statistical Analysis ...

Editorial 
Francesca M. Filbey, PhD

The changes in legislation surrounding cannabis use in the United States and worldwide have placed researchers in a race against time to get ahead of potential pitfalls and quagmires that come with venturing into the unknown of whether cannabis affects the brain. Statistics illustrating that 4.2 million (60.9%) ...

Editorial 
Matthijs G. Bossong, PhD; René S. Kahn, MD, PhD

An important and so far minimally addressed aspect of psychosis research is the manifestation of genetic psychosis susceptibility, as measured with polygenic risk profile scores (RPSs), on human brain function. The study of more than 1500 adolescents by Lancaster et al1 in this issue of JAMA Psychiatry...

Original Investigation 
Thomas M. Lancaster, PhD; David E. Linden, MD, PhD; Katherine E. Tansey, PhD; Tobias Banaschewski, MD, PhD; Arun L. W. Bokde, PhD; Uli Bromberg, Dipl-Psych; Christian Büchel, MD; Anna Cattrell, PhD; Patricia J. Conrod, PhD; Herta Flor, PhD; Vincent Frouin, PhD; Jürgen Gallinat, MD; Hugh Garavan, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot, MD, PhD; Marie-Laure Paillère Martinot, MD, PhD; Eric Artiges, MD, PhD; Herve Lemaitre, PhD; Frauke Nees, PhD; Dimitri Papadopoulos Orfanos, PhD; Tomáš Paus, MD, PhD; Luise Poustka, MD; Michael N. Smolka, MD; Nora C. Vetter, PhD; Sarah Jurk, Dipl-Psych; Eva Mennigen, MD; Henrik Walter, MD, PhD; Robert Whelan, PhD; Gunter Schumann, MD; for the IMAGEN Consortium
Includes: Supplemental Content

Importance  Psychotic disorders are characterized by attenuated activity in the brain’s valuation system in key reward processing areas, such as the ventral striatum (VS), as measured with functional magnetic resonance imaging.

Objective  To examine whether common risk variants for psychosis are associated with individual variation in ...

Editorial: The Salience of Reward; Matthijs G. Bossong, PhD; René S. Kahn, MD, PhD
Original Investigation 
Meghan E. Martz, MS; Elisa M. Trucco, PhD; Lora M. Cope, PhD; Jillian E. Hardee, PhD; Jennifer M. Jester, PhD; Robert A. Zucker, PhD; Mary M. Heitzeg, PhD
Includes: Supplemental Content

Importance  Marijuana use may alter ventral striatal response to reward, which might heighten susceptibility to substance use disorder. Longitudinal research is needed to determine the effects of marijuana use on neural function involved in reward response.

Objective  To determine whether marijuana use among young adults prospectively ...

Editorial: Weeding Through Marijuana’s Effects on the Brain; Francesca M. Filbey, PhD

Pediatric obsessive-compulsive disorder (OCD) is treated effectively with cognitive behavior therapy (CBT). However, there is clearly room for further improvement, and the exposure strategies used in this treatment are often distressing to patients. Therefore, it is desirable to improve the efficacy of CBT or to accelerate the treatment ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts